Indication
Colorectal cancer
- Cancer with high metastatic potential
- Drug penetration challenges
- Biomarker : Difficulty in targeted therapy
- Immunotherapy : Limited efficacy
-
Unmet needs
- High prevalence and metastasis rate
- Limitation of current therapies
- Drug development based on novel biomarker
-
Mode of Action
- ED1 secreted from colorectal cancer cells binds to Laminin332 in tumor microenvironment, resulting in increased cancer cell survival, growth, migration, and invasion.
- ED1 neutralizing antibody poses anti-tumorigenic and anti-metastatic efficacy by preventing ED1-Laminin332 interaction.
-
Core competitiveness
- Target feasibility confirmed in animal models and human specimen
- ED1 diagnostic tools applicable to human have been established
- ED1 antibody is under pre-clinical development stage
Development status
Efficacy study with ED1 antibody candidates